Blood
Articles in this Issue
Direct thrombin inhibition by paraprotein in multiple myeloma: A rare mechanism of paraprotein-mediated coagulopathy, corrected with myeloma therapy
Abstract Background Paraproteins, in monoclonal gammopathies, may lead to a range of coagulopathies. Direct thrombin inh...
Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies
Abstract Inobrodib (Ino, CCS1477) is a first in class potent, selective, and orally bioavailable inhibitor of the bromodomains of p300 and C...
Social determinants and hospital outcomes in Waldenström's macroglobulinemia: A nationwide analysis
Abstract Background: Waldenström's macroglobulinemia (WM) is a rare B-cell malignancy with limited data on inpatient outcomes and the role o...
Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial
Abstract Introduction: Despite achieving a ‘good response’ with anti-C5 therapy (defined as hemoglobin [Hb] levels 10 to <12 g/dL), s...
Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results
Abstract Background: CAR T-cell therapy has shown promising early results in patients (pts) with SLE through deep depletion of the B-cell li...
Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice: A retrospective-prospective study by fondazione italiana linfomi (FIL)
Abstract Background: The next-generation Bruton's Tyrosine Kinase inhibitor (BTKi) Zanubrutinib (ZAN) was FDA approved in 2021 and reimburse...
Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death
Abstract Immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, are cornerstone therapies for multiple myeloma (MM). These...
Untargeted metabolomics and machine learning reveal novel non-invasive biomarker panels for diagnosis and risk stratification in extranodal NK/T-cell lymphoma
Abstract Extranodal NK/T-cell lymphoma (NKTCL) is a rare and highly aggressive malignancy with distinct epidemiological features, posing sig...
Efficacy of crizanlizumab in preventing vaso-oclusive crisis and hospitlalizations in sickle cell disease
Abstract Background: Sickle Cell Anemia (SCA) is the most common form of Sickle Cell Disease (SCD), defined by lifelong hemolytic anemia, pa...
Denatured albumin is a potent ligand mediating platelet activaiton, adhesion and aggregation
Abstract Introduction: Serum albumin is the most abundant plasma protein, comprising approximately 50-60% of total plasma proteins. While al...
Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes
Abstract Background Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive mature T-cell neoplasm associated with chronic HTLV-1 inf...
Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial
Abstract Clinical Background. Iberdomide is a novel, potent, oral CELMoD with clinically meaningful activity and favorable toxicity profile...
COVID-19 convalescent plasma utilization patterns among hospitalized u.s. Medicare beneficiaries ages 65 and older diagnosed with COVID-19, 2020-2021
Abstract Introduction: In August 2020, COVID-19 convalescent plasma (CCP) was authorized for emergency use for the treatment of hospitalized...
Subcutaneous daratumumab at home is a safe and effective procedure allowing active treatment of frail patients with multiple myeloma
Abstract Treatment of Multiple Myeloma (MM) is often difficult due to patient (pts) frailty, bone lesions/fractures that can hinder transpor...
Real-world impact of high-risk cytogenetics and revised ISS (R2 ISS) on response and survival in multiple myeloma patients treated with various induction regimens: A single-center study from India.
Abstract Background: Multiple myeloma (MM) is a genetically heterogeneous malignancy in which cytogenetic abnormalities play a crucial role...
Adaptation, refinement and clinical correlation of a pharmacokinetics model for patients receiving anti-T-lymphocyte globulin as part of their conditioning regimen: Advances towards individualized dosing.
Abstract Introduction Despite the advantages of including anti-thymocyte globulin (ATG) or anti-T-lymphocyte globulin (ATLG) in the conditio...
Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma
Abstract Introduction: IEC-HS is an emerging and potentially life-threatening complication in multiple myeloma (MM) patients (pts) treated w...
Phase 2 study of SLS009 in combination with azacitidine and venetoclax for relapsed/refractory AML with MDS-related changes (AML-MR) after prior venetoclax treatment
Abstract Background Azacitidine plus venetoclax (AZA/VEN) improves overall survival in older or unfit patients with newl...
Tracing malignant precursor mutations and their cellular origins in blood and bone marrow of primary central nervous system lymphomas by ultrasensitive genomic profiling
Abstract Introduction Primary central nervous system lymphomas (PCNSL) are aggressive extranodal non-Hodgkin lymphomas confined to the CNS,...
The association of a novel psychosocial and mobility assessment with outcomes of veterans with acute myeloid leukemia (AML)
Abstract Background: Real-world outcomes of AML patients are consistently inferior to those of pivotal clinical trials, partly due to psycho...
Persistent and emerging racial gaps in mortality from malignant hematologic malignancies, 2018–2023
Abstract Background Malignant hematologic malignancies, encompassing leukemia, lymphoma, and myeloma, remain a significant cause of cancer-r...
An open-label rollover study to assess the long-term safety of ixazomib
Abstract Introduction: Long-term parenteral proteasome inhibitor (PI)-based therapy can prove challenging due to the burden of administratio...
Switching ITP patients to avatrombopag from other TPO-ras: A real-world experience of the spanish ITP group (GEPTI).
Abstract Avatrombopag (AVA) is the latest thrombopoietin receptor agonist (TPO-RA). The oral route of administration and the lack of drug an...
Activating STIM1 mutations drive the development of myelofibrosis
Abstract Myeloproliferative neoplasms (MPNs) are typically ascribed to hyperactive JAK-STAT signaling via mutations in JAK2, CALR, or MPL. H...
Thrombotic events as initial presentation of acute promyelocytic leukemia (APL): A literature-based review of patient-level data
Abstract Background: Bleeding is a well-established complication of acute promyelocytic leukemia (APL), driven by disseminated intravascular...